FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
148 letters match. Newest first.
-
DrugsRonanRx, Inc. dba RonanRx
FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsCheap Medicine Shop/www.cheapmedicineshop.com
FDA warned India-based website Cheap Medicine Shop for selling unapproved, misbranded injectable semaglutide to U.S. consumers.
High risk -
DrugsOnline Generic Medicine/www.onlinegenericmedicine.com
FDA warned Online Generic Medicine that its website sells unapproved, misbranded injectable semaglutide to U.S. consumers.
High risk -
DrugsEmpower Clinic Services, LLC dba Empower Pharmacy
FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.
High risk -
DrugsPeak Performance Peptides
Peak Performance Peptides sold unapproved injectable peptide drugs, including semaglutide and retatrutide, without FDA approval.
High risk -
DrugsRoyal Peptides LLC
FDA warned Royal Peptides LLC that seven peptide products sold on its website are unapproved new drugs.
High risk -
DrugsPeptide Partners LLC
Peptide Partners LLC sold seven unapproved injectable peptide drugs online with disease-treatment claims, FDA says.
High risk -
DrugsTXP Innovations LLC dba Tex Peptides
FDA warned Dallas peptide seller TXP Innovations (Tex Peptides) that its website sells unapproved injectable drugs, including semaglutide and tirzepatide.
High risk -
DrugsNativeMed LLC dba NativeMed
FDA warned telehealth seller NativeMed that its website misbranded compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsHydraMed IV LLC dba HydraMed
FDA told Denver telehealth seller HydraMed its website misbrands compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsNexus Health Solutions LLC dba Harper Meds
FDA warned telehealth seller Harper Meds that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.
Low -
DrugsFitRX, LLC dba AM RX
FDA warned telehealth seller AM RX that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.
Medium -
DrugsAltru Telehealth, LLC dba Altru Telehealth
FDA warns Altru Telehealth that its website falsely claimed compounded semaglutide/tirzepatide and compounding pharmacies were FDA-approved.
Low -
DrugsEden Health International Inc. dba Eden
FDA warned Eden Health International that its telehealth website misbrands compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsTrinity HealthCare Supply, LLC dba altRx
FDA warns altRx over misleading website claims for compounded semaglutide and tirzepatide, including 'clinically proven' and wrong compounder label.
Low -
DrugsAmie Health, Inc. dba Amie
FDA warned telehealth seller Amie Health that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.
Medium -
DrugsThrivelab Co. dba Thrivelab
FDA warned telehealth seller Thrivelab that its website misbrands compounded semaglutide with false claims suggesting FDA approval.
Medium -
DrugsVivioMD Group LLC dba VivioMD
FDA warned VivioMD that its website misbrands compounded semaglutide and tirzepatide by implying VivioMD is the compounder.
Low -
DrugsGlow Medispa, LLC dba Mint Med
FDA warns telehealth seller Mint Med that its website labels falsely suggest it compounds the semaglutide and tirzepatide drugs it sells.
Low -
DrugsNexlife Inc. dba Nexlife
FDA warned Nexlife that its website labels for compounded semaglutide and tirzepatide falsely suggest Nexlife is the compounder.
Low -
DrugsPublic Health Solution LLC dba DrMedHealth
FDA warned DrMedHealth over false website claims that compounded semaglutide and tirzepatide have the same active ingredient as Ozempic and Mounjaro.
Low -
DrugsD&H Medical Services
FDA warned D&H Medical Services that its website falsely suggests its compounded semaglutide and tirzepatide are the same as FDA-approved brand drugs.
Low -
DrugsMomentum Health 360 dba Momentum Health
FDA warned Momentum Health over false claims for compounded semaglutide, tirzepatide, and liraglutide.
Low -
DrugsMedica Weight Loss
FDA warns telehealth seller Medica Weight Loss that its compounded semaglutide and tirzepatide web claims are false and misbrand the drugs.
Medium -
DrugsEzra Holdco LLC dba Ezra
FDA says Ezra's website misbrands compounded semaglutide and tirzepatide by labeling them as Ezra-made when they are not.
Low -
DrugsReady Med
FDA warned Ready Med over website claims that compounded semaglutide and tirzepatide products were FDA-approved or FDA-licensed.
Low -
DrugsFITISH
FDA warned FITISH over misleading website claims for compounded semaglutide and tirzepatide, including labels suggesting it is the compounder.
Low -
DrugsOrderlyMeds LLC dba OrderlyMeds
FDA warned OrderlyMeds over website claims for compounded semaglutide and tirzepatide, saying its labels and 'FDA-licensed pharmacy' claim are misleading.
Low -
DrugsRoen Health, Inc. dba RoenRx
FDA warned RoenRx that its website misbrands compounded semaglutide with misleading approval claims and a company label implying it makes the drug.
Medium -
DrugsJoi and Blokes dba Joi + Blokes
FDA warned telehealth seller Joi + Blokes that its website misbrands compounded semaglutide and tirzepatide with false, misleading claims.
Medium -
DrugsNova Vascular LLC dba NOVARX
FDA warned NOVARX over false website claims that compounded semaglutide and tirzepatide products are FDA-approved or from FDA-approved pharmacies.
Low -
DrugsClover Meds LLC dba Clover Meds
Clover Meds, a telehealth seller, misbranded compounded semaglutide and tirzepatide with false website claims that it makes the drugs and uses 'FDA-licensed' facilities.
Medium -
DrugsMaximus Health, Inc. dba Maximus
FDA warned Maximus Health that its website makes false or misleading claims about compounded semaglutide and tirzepatide.
Low -
DrugsHarbin Jixianglong Biotech Co., Ltd.
FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.
High risk -
DrugsProRx LLC
ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.
High risk -
DrugsNew Life Pharma LLC
New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.
High risk -
DrugsPrime Sciences
Prime Sciences sells injectable peptide drugs and BAC water online without FDA approval, FDA says.
High risk -
DrugsApothecary Pharma, LLC
FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.
High risk -
DrugsNovo Nordisk Inc.
FDA warns Novo Nordisk over failures to report and investigate serious unexpected adverse drug experiences for drugs including semaglutide.
High risk -
DrugsPremium Health Management Inc. dba Premium Health
FDA warns Premium Health over misleading website claims for compounded semaglutide and tirzepatide.
Low -
DrugsLean Rx, Inc. dba SkinnyRx
SkinnyRx's website misbranded compounded semaglutide and tirzepatide by wrongly suggesting it makes the drugs and that they are FDA-approved.
Low -
DrugsKare Solutions, LLC dba Zappy
FDA warned Zappy that its website falsely suggested it compounds semaglutide, tirzepatide, and liraglutide and made misleading approval-like claims.
Low -
DrugsStrut Health, LLC dba Strut
FDA says Strut Health's website falsely labeled compounded semaglutide and tirzepatide as its own and FDA-approved.
Low -
DrugsRefills Health, LLC dba Refills Health
FDA told telehealth seller Refills Health its website misbrands compounded semaglutide by implying FDA approval and naming itself as maker.
Medium -
DrugsWeightless Medical LLC dba WeightCare
FDA warned telehealth seller WeightCare that its website falsely presents it as the compounder of semaglutide and tirzepatide drugs.
Low -
DrugsViv Health, Inc. dba VIV RX
FDA warned telehealth company VIV RX that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.
Medium -
DrugsPeaks Curative, LLC dba Peaks
FDA warned Peaks Curative over false or misleading website claims for compounded (pharmacy-made) semaglutide, including implied FDA approval.
Low -
DrugsPharmaZee
FDA warns PharmaZee over misleading website claims for compounded semaglutide and tirzepatide, including implying PharmaZee compounds them and that they are proven.
Low -
DrugsGood Girl LLC dba GoodGirlRX
FDA warns telehealth seller GoodGirlRX that its website misbrands compounded semaglutide and tirzepatide, claiming FDA approval and implying it is the compounder.
Medium -
DrugsIvim Services LLC dba Ivim
FDA says Ivim's telehealth website mislabels compounded semaglutide and tirzepatide as Ivim-made when it is not the compounder.
Low